Although only two SLE patients were included in this study, administration of ipilimumab (antibody against CTLA-4) to treat advanced melanoma in patients with pre-existing autoimmune diseases was associated with higher rates and severity of adverse events than general cancer populations and 27% of patients experienced exacerbation of their autoimmune condition [201]. This evidence concerns the gene CTLA4 and autoimmune disease.